NCT05440799

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1819479 in Healthy Female Subjects of Non-childbearing Potential (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: Female
• Age: 18 Years – 67 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy female subjects of non-childbearing potential.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 1819479	BI 1819479
DRUG	BI matching placebo	BI matching placebo

Timeline

• Start date: 2022-07-20
• Primary completion: 2023-08-02
• Completion: 2023-08-02
• First posted: 2022-07-01
• Last updated: 2023-08-14

Locations

1 site across 1 country: Germany